Amneal Refinances Term Loan With $2.1 Billion Loan and $600 Million Notes
On August 1, 2025, Amneal Pharmaceuticals LLC borrowed $2.1 billion of new seven-year term loans and completed a $600 million offering of 6.875% senior secured notes due 2032. The company used the proceeds to refinance its existing term loans, which had about $2.26 billion outstanding, and to repay its ABL facility in full. The filing describes a refinancing that replaces existing debt and extends maturities rather than adding a stated new use of cash.
Key points
- New $2.1 billion term loan matures August 1, 2032, with interest at term SOFR plus a 3.50% margin
- $600 million of 6.875% senior secured notes due August 1, 2032, issued at 100% of principal amount
- Existing term loan of about $2.26 billion refinanced in full; ABL facility repaid and its maturity extended to August 1, 2030 with $600 million of commitments
The filing
Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 01, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.